Elanco Animal Health Incorporated (NYSE:ELAN) Given Consensus Recommendation of “Hold” by Analysts

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have earned a consensus recommendation of “Hold” from the seven research firms that are currently covering the company, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $15.17.

Several analysts recently issued reports on ELAN shares. Stifel Nicolaus lifted their target price on Elanco Animal Health from $15.00 to $16.00 and gave the company a “buy” rating in a research note on Monday, May 19th. Barclays reduced their price objective on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. Piper Sandler reduced their price objective on Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating on the stock in a research note on Thursday, March 6th. Morgan Stanley reduced their price objective on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 26th. Finally, UBS Group reduced their price objective on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Wednesday, February 26th.

Elanco Animal Health Stock Down 2.5%

Shares of ELAN opened at $13.82 on Monday. The business’s 50 day moving average is $11.38 and its 200 day moving average is $11.42. The company has a market capitalization of $6.86 billion, a PE ratio of 34.55, a price-to-earnings-growth ratio of 2.50 and a beta of 1.67. Elanco Animal Health has a 12-month low of $8.02 and a 12-month high of $18.55. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Wednesday, May 7th. The company reported $0.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.06. The company had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm’s quarterly revenue was down 1.0% on a year-over-year basis. During the same quarter last year, the company earned $0.34 EPS. Research analysts expect that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Elanco Animal Health

A number of institutional investors and hedge funds have recently modified their holdings of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Elanco Animal Health by 4.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company’s stock worth $18,830,000 after purchasing an additional 76,408 shares during the period. Empowered Funds LLC boosted its holdings in shares of Elanco Animal Health by 35.2% in the 1st quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock worth $166,000 after purchasing an additional 4,121 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of Elanco Animal Health by 104.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after purchasing an additional 2,445,872 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Elanco Animal Health in the 1st quarter worth approximately $2,065,000. Finally, AQR Capital Management LLC boosted its holdings in shares of Elanco Animal Health by 116.4% in the 1st quarter. AQR Capital Management LLC now owns 524,507 shares of the company’s stock worth $5,332,000 after purchasing an additional 282,081 shares during the period. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.